Abstract
Multi-organ biological aging clocks derived from clinical phenotypes and neuroimaging have emerged as valuable tools for studying human aging and disease1,2,3,4. Plasma proteomics provides an additional molecular dimension to enrich these clocks5. Building on previous work1,3, I developed 11 multi-organ proteome-based biological age gaps (ProtBAGs) using 2448 plasma proteins from 43,498 participants in the UK Biobank. I highlighted key methodological and clinical considerations for developing and using ProtBAG, including age bias correction6, and investigated the impact of training data sample size, protein organ specificity, and the underlying pathologies of the training data on model generalizability and clinical interpretability. I then integrated the 11 ProtBAGs with our previously developed 9 multi-organ phenotype-based biological age gaps (PhenoBAG1) to investigate their genetic underpinnings, causal associations with 525 disease endpoints (DE) from FinnGen and PGC, and their clinical potential in predicting 14 disease categories and mortality. Genetic analyses revealed overlap between ProtBAGs and PhenoBAGs via shared loci, genetic correlations, and colocalization signals. A three-layer causal network linked ProtBAG, PhenoBAG, and DE, exemplified by the pathway of obesity→renal PhenoBAG→renal ProtBAG to holistically understand human aging and disease. Combining features across multiple organs improved predictions for disease categories and mortality. These findings provide a framework for integrating multi-organ and multi-omics biological aging clocks in biomedicine. All results are publicly disseminated at https://labs-laboratory.com/medicine/.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
NA
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The UKBB data has its own IRB and Ethics Committees, and we requested the data under approved applications. The IRB for the MULTI consortium is in progress.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Revision after first-round peer review
Data Availability
The GWAS summary statistics corresponding to this study are publicly available on the MEDICINE knowledge portal (https://labs-laboratory.com/medicine/). Our study used data generated by the human protein atlas (HPA: https://www.proteinatlas.org). GWAS summary data for the DEs were downloaded from the official websites of FinnGen (R9: https://www.finngen.fi/en/access_results) and PGC (https://pgc.unc.edu/for-researchers/download-results/). Individual data from UKBB can be requested with proper registration at https://www.ukbiobank.ac.uk/. Certain sensitive data (e.g., allele frequency information) supporting the findings are also available from the author upon request.
